Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Not yet recruiting3
Completed1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

completed117%
active_not_recruiting117%
not_yet_recruiting350%
recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_1

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

NCT07570186
recruitingphase_1

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

NCT05257993
not_yet_recruitingphase_2

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

NCT07370818
not_yet_recruitingphase_1

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

NCT07364422
active_not_recruitingphase_2

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

NCT05475184
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07570186Phase 1

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

Not Yet Recruiting
NCT05257993Phase 1

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
NCT07370818Phase 2

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Not Yet Recruiting
NCT07364422Phase 1

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Not Yet Recruiting
NCT05475184Phase 2

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Active Not Recruiting
NCT04335604Phase 1

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6